BPC-157 & TB-500 (10/10mg) – BB20

BPC-157 & TB-500 Blend (10mg/10mg) — Research Peptide

The high-dose BPC-157 and TB-500 combination at 10mg/10mg per vial is designed for research protocols requiring elevated concentration ranges or extended experimental timelines. This format provides the same complementary dual-mechanism profile as the 5mg/5mg blend, with double the compound mass per vial for larger-scale or multi-arm experimental designs.

Research Applications

The 10mg/10mg format is particularly suited to research contexts where:

• Higher dose ranges need to be explored in dose-escalation studies
• Multiple experimental groups require identical batch sourcing
• Extended in vivo protocols (12+ week models) require consistent supply
• In vitro work requires high-concentration stock solutions

Compound Profiles

BPC-157 (10mg): Pentadecapeptide studied in tendon, ligament, muscle, gastrointestinal, and neurological research models. Primary mechanism: VEGFR2-Akt-eNOS angiogenic pathway and EGR1-mediated collagen gene expression.

TB-500/Tβ4 fragment (10mg): Actin-sequestering peptide fragment studied in wound healing, cardiac progenitor mobilisation, and skeletal muscle satellite cell research. Primary mechanism: G-actin sequestration enabling lamellipodia formation and directed cell migration.

Product Specifications

• Peptides: BPC-157 (10mg) + TB-500/Tβ4 fragment (10mg)
• Format: Co-lyophilised powder blend, bulk box of 10 vials
• Purity: ≥98% per component, Janoshik HPLC verified
• Testing: Full Janoshik COA available on request
• Storage: -20°C lyophilised. 24-month stability.

For laboratory research use only. Not for human therapeutic use.